HKSE:06922 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:06922 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cryofocus Medtech (Shanghai) Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$-0.24. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.49.
Cryofocus Medtech (Shanghai) Co's EPS (Basic) for the six months ended in Jun. 2024 was HK$-0.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.49.
Cryofocus Medtech (Shanghai) Co's EPS without NRI for the six months ended in Jun. 2024 was HK$-0.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.49.
During the past 3 years, the average EPS without NRIGrowth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 4 years, Cryofocus Medtech (Shanghai) Co's highest 3-Year average EPS without NRI Growth Rate was 13.00% per year. The lowest was 13.00% per year. And the median was 13.00% per year.
The historical data trend for Cryofocus Medtech (Shanghai) Co's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EPS (Diluted) | -0.68 | -0.52 | -0.55 | -0.45 |
Cryofocus Medtech (Shanghai) Co Semi-Annual Data | ||||||||
Dec20 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | ||
EPS (Diluted) | Get a 7-Day Free Trial | -0.21 | -0.33 | -0.20 | -0.25 | -0.24 |
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Cryofocus Medtech (Shanghai) Co's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
Diluted EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-106.628 | - | 0) | / | 239.110 | |
= | -0.45 |
Cryofocus Medtech (Shanghai) Co's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as
Diluted EPS (Q: Jun. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-56.164 | - | 0) | / | 239.110 | |
= | -0.23 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.49
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Wu Jianhui | 2101 Beneficial owner | |
Li Hui | 2202 Interest of your spouse | |
Lv Shiwen | 2103 Interests held jointly with another person | |
Sun Xiaolu | 2201 Interest of corporation controlled by you | |
Zhang Qian | ||
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi He Huo Qi Ye You Xian He Huo | ||
Shang Hai Shi Di Sheng Wu Ke Ji You Xian Gong Si | ||
Shang Hai Bi Lin Xing Zi Chan Guan Li You Xian Gong Si | ||
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi Guan Li He Huo Qi Ye You Xian He Huo | ||
Ning Bo Lin Feng Sheng Wu Ke Ji You Xian Gong Si | ||
Shang Hai Shi Di Shi Ye Fa Zhan You Xian Gong Si | ||
Sheng Shan Zi Chan Guan Li Shang Hai You Xian Gong Si | ||
Gan Shi Xiong | ||
Su Zhou Gong Ye Yuan Qu Zhi Nuo Shang Wu Xin Xi Zi Xun You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Su Zhou Gong Ye Yuan Qu Xin Jian Yuan Er Qi Chuang Ye Tou Zi Qi Ye You Xian He Huo | 2101 Beneficial owner |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.